In the process of searching for new medicines, many readily available fruits have been picked. But there are still many rewards to be discovered, and Atavistik Bio aims to discover it by looking for unknown places.Although still in its infancy, its technological prospects have aroused investors’ interest, leading to 60 million USD A round of financing.
The traditional working method of small molecule drugs is to bind to the active site on the protein, which is a pocket, which is the typical location where the two connect. However, some disease-related proteins lack these binding sites. Atavistik, based in Cambridge, Massachusetts, aims to discover and develop allosteric drugs that can bind to other less obvious places on proteins. The trick is to find those places.
Atavstik’s research focuses on metabolites, which are substances formed by cellular metabolic reactions. Scientists at Atavistik believe that metabolites are more than just by-products. John Josey, risk partner at The Column Group and acting CEO of Atavistik, said that enzymes have evolved over millions of years and are regulated by metabolites in well-defined pathways now. The name Atavistik refers to the phenomenon of reversion, which in biology is the reproduction of previous genetic characteristics. Josey said the company believes its approach is to use past knowledge and learn from evolution.
According to Marion Dorsch, the company’s president and chief scientific officer, Atavistik technology allows comprehensive screening of a large number of proteins for a large number of metabolites to discover their interactions. Artificial intelligence and machine learning techniques are used to explore and analyze data. With new knowledge of allosteric interactions, Atavstik will use traditional chemistry to design and develop small molecules that can exhibit the desired pharmacological effects. The startup’s initial goals were metabolic diseases and cancer, but Dorsch, a biotech industry veteran who recently served as a top scientist at Blueprint Medicines, said there are many potential applications.
“This is a platform-based approach, and we hope to continue over time, and we hope to achieve new goals and new drugs over time,” she said. “We are not a single asset company.”
Since Atavistik’s technology is a platform, Josey has opened the door to collaborations with large companies that may be involved in areas beyond the start-up’s disease focus. Atavistik technology comes from the laboratory of scientific co-founder Jared Rutter, a professor of biochemistry at the University of Utah, whose research includes new protein-metabolite interactions. Another scientific co-founder, Ralph DeBerardinis, is a professor and head of the Department of Pediatric Genetics and Metabolism at the University of Texas Southwestern Medical Center. Josey said DeBerardinis is an expert in metabolism and cancer. Their research, because it is particularly applicable to Atavistic, has not yet been published, although Josey said he expects to publish some papers in the coming months.
Atavistik’s colleagues in the search for targets for allosteric drugs are developing further. Gain Therapeutics raised $40 million In March, it supported the clinical test plan for its two main allosteric drug candidates, which are being developed to treat rare enzyme deficiencies.when Roivant Sciences announces the acquisition of Silicon Therapeutics for USD 450 million In February of this year, it stated that the startup’s artificial intelligence capabilities will help its drug research efforts, including allosteric inhibitors. Black Diamond Therapeutics’ main anti-cancer drugs have entered clinical trials The company’s metamorphic drug platform.
Josie said that Atavistik just came out of Rutter’s lab last month. The company’s first task is to establish its Cambridge business. Josey estimates that $60 million in funding will support the company for four years. In the first 18 months, technologies will be established to analyze many proteins, and preliminary screening of sites that may become binding sites for new drugs will be conducted. From there, the research will undergo laboratory testing and then preclinical research.
“I hope that in the next three years, we will have one or more molecules into the clinic,” Josey said.
The A round of financing was led by The Column Group. Other investors in this round are LUX Capital and Nextech Invest.
Photo by Atavistik Bio
